Caliway Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Caliway Biopharmaceuticals Co., Ltd., explained in plain language.
A Taiwan-based biopharmaceutical company developing treatments for inflammatory and fibrotic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New injection aims to melt belly fat without surgery Results expected Apr 2027 (estimated)
- Belly fat melting shot? phase 3 trial begins. Results expected May 2027 (estimated) 🚀 Make-or-break
- New shot aims to melt belly fat without surgery Results expected Aug 2027 (estimated) 🚀 Make-or-break
-
Belly fat melting shot? phase 3 trial begins.
Disease control Not yet recruitingThis Phase 3 trial tests whether an injection called CBL-514 can safely reduce abdominal fat. 300 adults with moderate to severe belly fat will receive either the drug or a placebo. The study measures fat loss by MRI and patient ratings over time.
Phase 3 • Sponsor: Caliway Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can an injection melt away belly fat for good?
Symptom relief Not yet recruitingThis trial is testing whether an experimental injection called CBL-514 can safely reduce stubborn belly fat. It is for people who already received the treatment or a placebo in an earlier study. Researchers are checking for side effects and whether fat reduction lasts over time.
Phase 3 • Sponsor: Caliway Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
New injection melts belly fat in clinical trial
Symptom relief Not yet recruitingThis study tests an injection called CBL-514 to see if it can safely reduce belly fat. About 250 adults with extra abdominal fat will receive either the injection or a placebo. The goal is to measure fat loss using MRI and doctor ratings.
Phase 2 • Sponsor: Caliway Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New shot aims to melt belly fat without surgery
Symptom relief Not yet recruitingThis phase 3 trial tests an injection called CBL-514 to see if it can safely reduce belly fat. About 320 adults with moderate to severe abdominal fat will receive either the drug or a placebo. The main goal is to see if more people in the drug group report a meaningful fat reduct…
Phase 3 • Sponsor: Caliway Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC